Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 -- -- Phase 3 PREVAIL CVOT remains on track -- -- ...

No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has potential in treating idiopathic pulmonary fibrosis, in healthy individuals, ...

Adcendo, a biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that the U.S. Food & Drug Administration (FDA) has ...

The results were alarming. Among PPI users, 5.6% reported kidney-related problems, compared to just 0.7% of those taking ...

Young people are experiencing distressing symptoms of sexual dysfunction and emotional numbness following antidepressant ...

New study shows dementia patients who are on antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), ...

Scientists at the (UNIGE) have developed a tool that uses light to precisely control where and when a drug becomes active, ensuring it works exactly where it's needed. For medical treatments to be ...

The data highlight the possibility of SGLT 1/2 inhibitors having protective effects beyond heart failure and diabetes.

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...